Buy Superlymph vaginal/rectal suppositories 25 units No. 10 in pharmacies
Release form: rectal and vaginal suppositories, 10 units, 25 units
Pharmacotherapeutic group: Tissue repair stimulator
ATX code: G04BX
Ingredients: active ingredient Superlymph® (substance), cocoa butter, anhydrous lanolin. Description: Suppositories are whitish-creamy in color, cone-shaped or cylindrical in shape. Heterogeneity in the form of inclusions or marbling is allowed.
Superlymph is a natural complex of natural antimicrobial peptides and cytokines - universal stimulants of the immune system with the activity of macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor (TNF), transforming growth factor (TGF) secreted by pig peripheral blood leukocytes. Antimicrobial peptides have a wide spectrum of direct antimicrobial activity - they inhibit the growth of microorganisms, fungi and some viruses. They are rightly called natural or endogenous antibiotics.
Immunobiological properties: Superlymph® is an immunomodulator with antiviral and antimicrobial effects. The drug stimulates the functional activity of phagocytic cells (monocytes and neutrophils): activates phagocytosis, the production of cytokines (IL-1, TNF), induces antitumor cytotoxicity of macrophages, promotes the death of intracellular parasites, regulates cell migration to the site of inflammation, increases the activity of natural killer cells. Superlymph® reduces the development of inflammatory reactions by reducing swelling, infiltration, hyperemia and pain. Stimulates regeneration, epithelization and formation of granulation tissue. Activates healing, acting on all stages of the wound process. Regulates the formation of scar tissue, preventing the formation of rough scars due to the synthesis of type IV collagen, which is especially important during reconstructive operations. Has antioxidant activity.
Indications for use: Complex treatment of herpetic diseases of the urogenital tract, including those complicated by bacterial and other viral infections.
Dosage regimen: for the treatment of a viral infection in the acute stage, Superlymph® 25 IU is used vaginally or rectally depending on the location and gender of the patient, if necessary, alternating the method of administration, 1 suppository 1 time per day. Course duration is 10 days.
To prevent a recurrence of a viral infection, use Superlymph® 10 units, 1 suppository 1 time per day, alternating rectal and vaginal routes of administration is possible. Course duration is 10 days.
In order to prevent possible relapses, repeated courses are allowed after 2-3 months and simultaneous treatment of both partners, as well as treatment of a partner if a herpetic infection is detected.
Side effect: not identified.
Contraindications for use: Superlymph® suppositories are not recommended for use at body temperatures above 38°C, or if there is a history of hypersensitivity to proteins of pork origin.
Special instructions: The drug is not suitable for use if the integrity of the packaging is damaged; without marking; with altered physical properties (change in color, smell of rancid fat, deformation of the suppository); expired.
Storage conditions and periods: the drug is stored and transported in accordance with the SP. 3. 3. 2. 1248 - 03 at temperatures from 2 to 8°C. The drug is stored out of the reach of children.
Shelf life: 2 years.
Conditions for dispensing from pharmacies: without a prescription.
Hotline for specialist consultation: 8-800-550-14-30
Superlymph supp vag and rect 25 units x10
INSTRUCTIONS for the use of the medicinal product for medical use SUPERLIMP®
rectal and vaginal suppositories 10 units, 25 units
Superlymph® is a natural complex of natural antimicrobial peptides and cytokines - universal stimulants of the immune system with the activity of macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor (TNF ), transforming growth factor (TGF), secreted by leukocytes of pig peripheral blood.
Superlymph® suppositories contain the active substance - Superlymph® substance, as well as cocoa butter and anhydrous lanolin.
Suppositories are whitish-creamy in color, cone-shaped or cylindrical. Inhomogeneity of color in the form of inclusions or marbling is allowed.
Immunobiological properties.
Superlymph® is an immunomodulator. Along with this, the drug has antiviral and antimicrobial effects.
The drug stimulates the functional activity of phagocytic cells (monocytes and neutrophils): activates phagocytosis, the production of cytokines (IL-1, TNF), induces antitumor cytotoxicity of macrophages, promotes the death of intracellular parasites, regulates cell migration to the site of inflammation, increases the activity of natural killer cells.
The drug has antioxidant activity, reduces the development of inflammatory reactions, stimulates regeneration and epithelization of wound defects.
Indications for use.
Superlymph® suppositories are intended for the complex treatment of herpetic diseases of the urogenital tract, including those complicated by bacterial and other viral infections.
Method of administration and dose.
Before administration, the packaging material is removed from the suppository. For the treatment of a viral infection in the acute stage, Superlymph 25 IU is used vaginally or rectally depending on the location and gender of the patient, if necessary, alternating the method of administration, 1 suppository once a day. Course duration is 10 days.
To prevent a relapse of a viral infection, use Superlymph 10 units, 1 suppository 1 time per day, alternating rectal and vaginal routes of administration is possible. Course duration is 10 days.
In order to prevent possible relapses, repeated courses are allowed in the amount of one after 2-3 months and simultaneous treatment of both partners, as well as treatment of a partner if a herpetic infection is detected in him.
Side effect.
Not found.
Contraindications.
Superlymph® suppositories are not recommended for use at body temperatures above 38 °C, or if there is a history of hypersensitivity to proteins of pork origin.
special instructions
The drug is unsuitable for use if:
- the integrity of the packaging is compromised, - without marking, - with altered physical properties (change in color, the appearance of the smell of rancid fat, deformation of the suppository), - with an expired expiration date.
Release form.
5 suppositories of 10 units or 25 units each in a blister pack (blister) made of EP-7ZS or imported PVC film. 2 blister packs (blisters) per pack with instructions for use.
Best before date.
Shelf life: 2 years. A drug that has expired cannot be used.
Storage and transportation conditions.
The drug is stored and transported in accordance with SP 3.3.2.1248-03 at a temperature of 2 to 8 °C. The drug is stored out of the reach of children.
Vacation conditions.
Available without a prescription.
, Russia 142073, Moscow region, Domodedovo district, Sudakovo village, d/o "Lesnoye" By order of LLC ", Russia 127106, Moscow, Altufevskoye sh., no. 27, floor 2, office 238/1
Complaints about the drug should be sent to the address of the owner of the registration certificate: LLC "127106, Moscow, Altufevskoe sh., 27, floor 2, office 238/1, tel.: +7
,
In recent years, there has been an increase in gynecological morbidity, including immune-related diseases with a predominance of chronic pathological processes. Of particular concern are the extremely negative trends in changes in the health status of children and adolescents, which further determine the reproductive health of the nation. Thus, the proportion of absolutely healthy girls has decreased over the past ten years from 28.6 to 6.3%; 75% of high school girls have various chronic somatic diseases, and by the beginning of the reproductive period, every teenager has at least one chronic disease. The incidence of gynecological pathology among high school girls has also doubled. All this leads to an increase in the number of diseases in pregnant women, and consequently to a complicated course of the gestational process, childbirth and the postpartum period, and disruption of the contractile function of the uterus.
According to WHO, more than 300 million cases of urogenital inflammatory diseases caused by sexually transmitted infections (STIs) are registered annually in the world; in general, STIs cause 40-60% of all inflammatory diseases of the urogenital tract in women, significantly disrupting the state of the vaginal microbiocenosis, causing abundant growth of opportunistic microflora [3, 4]. It should be noted that chronicity of the infectious process occurs in 50-70% of cases. The cause of re-infection and recurrence of genital infections is a violation of the local anti-infective resistance of the vaginal mucosa against the background of the development of secondary immunodeficiency.
In the pathogenesis of many diseases, a significant role is played by disorders in the immune system. According to modern concepts, inflammatory gynecological diseases are characterized by the development of secondary immune deficiency. In this case, the most pronounced changes are observed in certain parts of the immune system: the functional activity of monocytes/macrophages and neutrophils suffers, a defect in the interferon system is observed, and a change in the balance of pro- and anti-inflammatory cytokines occurs.
In this regard, in recent years, much attention has been paid to the use of cytokines as drugs. Currently, pathogenetic drugs are increasingly used in the clinic, the therapeutic effects of which are carried out through the regulation of pathological processes in the body using physiological mechanisms. A promising direction in this area is topical cytokine therapy. At their core, cytokines are universal mediators of intercellular interactions, i.e. those molecules with which the cells of the immune system and other body systems “communicate” with each other. The biological role of these regulatory peptides is undeniable in the development of a wide range of pathophysiological processes: tissue damage and inflammation, as well as repair and regeneration processes [2-4].
A feature of cytokine therapy is its physiological action, at the same time it affects the pathogenesis of various diseases and normalizes the functioning of the immune system. When the mechanisms of cell activation are insufficient, the use of cytokines as a therapeutic agent leads to increased functional activity of cells of the immune system, and when these cells are hyperactive, an additional dose of cytokines causes a decrease in their activity. Naturally, this effect justifies the use of cytokines in a wide range of diseases [3].
A positive result of the use of local cytokine therapy as part of a complex therapy was the regulation of the level of excretion of the dominant representatives of the microbiocenosis of the vagina and cervix - lactobacilli and bifidobacteria, which was not observed in the groups of examined patients without the use of local cytokine therapy. In addition, only in these groups did the previously existing excessive growth of opportunistic microflora completely disappear.
Local cytokine therapy is used in the treatment of diseases of various etiologies, accompanied by inflammation and impaired repair, as well as in the treatment of inflammatory diseases, accompanied by the development of local immunodeficiency.
The criteria for the use of cytokine therapy for various gynecological diseases are the presence of chronic recurrent infections of a bacterial and viral nature in various parts of the genitourinary system, disruption of reparative processes in the skin and mucous membranes of the tissues after surgery, trauma, inflammatory diseases of the pelvic organs and uterus. These diseases are accompanied not only by systemic immune disorders, but also by defects in immune processes in the mucous membranes and tissues of the reproductive tract of women. The effectiveness of local application of the drug Superlymph has been studied in complex therapy of patients with chronic inflammatory diseases: salpingo-oophoritis, endometritis, viral and bacterial infections of the urogenital tract. The drug was also used for the prevention and treatment of purulent-septic complications after cesarean section and corrective operations of the perineum, endoscopic treatment of tubal-peritoneal infertility, in the treatment of patients with diseases of the cervix, including the presence of papillomavirus infection (PVI), cytomegaly, herpesvirus infections, with bacterial vaginosis, papillomas and condylomas of the external genitalia.
Cytokine therapy improves healing at all stages of the wound process, regulates collagen synthesis and proliferative activity of fibroblasts in the skin and mucous membranes.
The immunotropic drug superlymph is a standardized complex of cytokines, among which the activity of interleukins (IL-1, 2, 6), tumor necrosis factor α (TNF-α), phagocyte migration inhibitory factor (MIF), transforming growth factor (TGFr) has been determined. Superlymph is a natural complex of biologically active antimicrobial peptides and cytokines obtained from porcine leukocytes that regulate innate (natural) and acquired (adaptive) immunity. The drug has a direct antimicrobial effect. The molecular mechanism is to increase the concentration of intracellular calcium ions, to modulate the oxygen metabolism of phagocytic cells with their subsequent activation. The drug is available in suppositories of 25 units in 1 suppository for vaginal or rectal administration, as well as in the form of a lyophilisate for the preparation of a solution for local and external use in ampoules of 0.1 mg.
Superlymph is a natural complex of natural peptides (cytokines) developed at the Department of Immunology at the Russian State Medical University. The mechanism of action and clinical effectiveness of the drug has been studied for more than 15 years. It has a wide range of biological activities that regulate immune processes. Does not cause side effects, harmless to the body.
Contraindications to the use of cytokine therapy are individual intolerance, deep fistulas, body temperature above 38 ° C, as well as a history of hypersensitivity to proteins of pork origin.
Complex therapy of underlying cervical diseases
Pathology of the cervix is the most common, mainly in young women, and tends to be protracted and recur after treatment. Background diseases of the cervix occupy one of the leading places in the structure of gynecological pathology and carry the risk of developing precancerous changes and cervical cancer, which continues to occupy one of the leading places in the structure of cancer incidence [1]. Background diseases of the cervix also lead to a significant decrease in fertility and deterioration in the quality of life of patients [5]. In general, benign pathological processes in the cervix make up about 55% of diseases in gynecological patients and about 80% in the structure of cervical pathology. In the structure of the actual background processes of the cervix, the leading place is occupied by ectopia, the frequency of which is 38.8%, and in nulliparous women under 25 years of age - up to 54.2%.
The problem of treating underlying cervical diseases in terms of preventing the development of cervical cancer remains an urgent problem.
Despite the availability of numerous treatment methods, recurrence of background processes of the cervix remains at a high level. These diseases, as a rule, are accompanied not only by systemic immune disorders, but also by defects in immune processes in the mucous membranes and tissues of the reproductive tract of women. Based on the above, it is timely to develop comprehensive methods for the treatment and prevention of background processes of the cervix.
The clinical effect is expressed in the elimination of inflammation and activation of reparative processes caused by an increase in the phagocytic activity of immune system cells, activation of cytotoxicity, production of cytokines (IL-1, TNF-α), and antioxidant activity of the drug.
Under the influence of a complex of cytokines, collagen synthesis and proliferative activity of fibroblasts are regulated. Regulation of all stages of the wound process by a natural complex of cytokines ensures the wound healing effect of the drug.
An important aspect of the action of the cytokine complex (superlymph) is not only the regulation of immune and regenerative processes, but also the control of the spectrum of microflora (bacteria and, including viruses). In addition, Superlymph blocks the replication of HSV-1 in cultured human epithelial cells.
A positive result of the use of local cytokine therapy as part of complex therapy was the normalization of the level of isolation of the dominant representatives of the microbiocenosis of the vagina and cervix - lactobacilli and bifidobacteria, which was not observed in the groups of examined patients without the use of cytokine therapy. In addition, only in these groups did the previously existing excess growth of opportunistic flora completely disappear. As a result of the treatment, all examined patients showed a tendency to restore disturbances in the vaginal microbiocenosis. The duration of the effect of the complex treatment of underlying diseases in combination with STIs was confirmed during a control colposcopic study of the examined patients 6 months after the start of treatment.
Superlymph is used in the treatment of diseases of various etiologies, accompanied by inflammation and impaired repair, acute and chronic inflammatory diseases associated with the development of local immunodeficiency: damage to the cervix by the human papillomavirus (HPV), cytomegalovirus and herpes virus, for the complex treatment of damage to the cervix by the herpes virus in combination with diseases of the cervix, including those complicated by bacterial and viral infections, treatment and prevention of purulent-septic complications and, including after surgery, ectopia of the cervix, endocervicosis, cervicitis, condylomas, papillomas of the external genitalia [5, 6 ].
Superlymph is used for local use in the form of vaginal suppositories 25 mcg (1 suppository) before and after surgery 1 time per day for 5 days.
For the treatment of recurrent diseases of the cervix, superlymph 25 units is used vaginally, 1 suppository 1 time per day (at night) after corrective action. The duration of the course is up to 5-7 days, 1-2 courses are used. In order to prevent relapses, repeated courses are possible after 1-3 months. To prevent relapse, use superlymph 10 units, 1 suppository, 1 time per day vaginally. Course duration is 7-10 days.
The role of cytokines in the prognosis and prevention of the oncological process
The current trend is a significant increase in morbidity among young women, who represent not only a reproductively significant part of the population, but also a socially active group. Moreover, in the age group from 20 to 40 years, cervical cancer is the main cause of death among all patients with malignant neoplasms of the female genital area, reaching 60%. It is generally accepted that the problem of cervical tumors is associated not only with a persistently high incidence of cancer, but also with difficulties in diagnosing epithelial dysplasia, which is one of the stages of malignancy of the cervical epithelium. According to WHO experts, cervical cancer is a completely preventable disease if it is detected at the precancer stage.
Considering the potential risk of malignant transformation of the cervical epithelium, a determining role is assigned to prognostic criteria for the occurrence and development of cervical neoplasia.
In recent years, the incidence of PVI, characterized by high contagiousness, has sharply increased. PVI has the ability to initiate malignant tumors in the body, in particular carcinoma. Cervical PVI is a precursor
neoplastic changes in the cervix. It is believed that these processes occur in patients with immunosuppression. There are no specific antiviral drugs for the treatment of PVI, and therefore only properly selected complex therapy leads to the complete disappearance of condylomas, including high-oncogenic HPV.
It has been proven that the presence of PVI contributes to the occurrence of precancerous diseases, but HPV infection does not always cause the development of a neoplastic process. It is known that the development of the neoplastic process, sometimes in combination with HPV, is accompanied by impaired immunity and hemostasis. Cytokines ensure interaction between cells of the immune and phagocytic systems and hemostasis. In patients with mild and moderate cervical dysplasia, compared with values in healthy women, a 5-fold increase in the concentrations of IL-1α and IL-1β (p<0.001) was found against the background of relatively low levels of IL-8 and TNF-α. At the same time, in another group of patients, a significant increase in the blood serum was found not only of molecules of the IL-1 family, but also of IL-8 and TNF-α molecules (p<0.001). An increase in the level of pro-inflammatory cytokines is due to stimulation of macrophages by tumor antigens and can serve as an indirect indicator of activation of the hemostasis system, and the expression of tissue factor, in turn, can reflect the degree of stimulation of immunocompetent cells.
Thus, it can be assumed that the level of cytokines and tissue factor expression in patients with severe dysplasia and cervical cancer can indirectly judge the degree of malignancy of the tumor process and evaluate the effectiveness of the treatment [6].
Topical cytokine therapy for superlymphomas is pathogenetically justified in the treatment of PVI, since the drug has both direct antiviral and immunomodulatory effects.
Work to study the effectiveness of including superlymph in complex therapy for PVI was carried out at the Moscow City Center for DNA Research by Associate Professor, Ph.D. T.A. Krasnova.
Study groups: 30 patients suffering from PVI, complex treatment using superlymph, and a control group - 20 patients with the same pathology without the use of cytokine therapy.
The average age of patients was 22.5 years (from 17 to 41 years). All patients complained of itching, burning in the genital area, perineum, leucorrhoea, pain during urination, and dyspareunia. In 70% of patients in both groups, other STIs were identified: mycoplasma infection, chlamydia, herpes and cytomegalovirus infections, bacterial vaginosis.
Diagnosis of PVI was based on detection of HPV using the polymerase chain reaction method. Smears were taken both from the site of localization of condylomas and always from the cervix. High oncogenic risk HPV (types 16, 18) and low-risk HPV (types 6, 11, 44) were determined. An extended colposcopy and cytological examination of the ecto- and endocervix (Pap test) were performed.
These studies were carried out before treatment and monthly after complex therapy for 4 months.
As a result of the examination, HPV of both high and low oncogenic risk was detected in 90.2% of patients. Cytological examination revealed signs characteristic of HPV lesions of the cervix in 20% of patients - koilocytosis.
To treat patients with PVI, combination therapy was used, combining systemic and local treatment. Chemical coagulation was used as local therapy to remove condylomas.
The drug superlymph - suppositories containing 25 mcg of active substance, was administered daily for 10 days, alternating intravaginal and rectal administration every other day.
The disappearance of condylomas was observed in all patients of both groups within 2 weeks after the end of treatment. Relapse of condylomatosis was detected in 15% of patients within the next 3 months after therapy in the group without the use of local cytokine therapy. In the experimental group, relapse was detected in only 1 (3.3%) patient [3, 6].
The role of cytokines in miscarriage
Currently, the problem of miscarriage, in particular non-developing pregnancy, remains significant in the structure of reproductive losses. The share of this pathology in the structure of reproductive losses is quite high - 10-20% [4].
Immune aspects of miscarriage in 40-50% of cases manifest themselves in the form of pathological changes at various levels of the immune system, as well as an inadequate response of the mother’s body to paternal antigens (allogeneic immune response). It has been established that in most cases, termination of pregnancy is mediated by natural killer cells (NK) and macrophages [8].
The endometrium of women who have not had recurrent miscarriages produces Th2 (cytokines IL-4 and IL-6), while cytokines produced by Th1 (such as IL-2, IL-12 and IFN-γ) predominate in the endometrium of women suffering from recurrent miscarriages. miscarriage of unknown etiology [9].
Proinflammatory cytokines (IFN-γ and TNF-α) stimulate villous cytotrophoblast apoptosis. IL-2 can damage the trophoblast, promoting the conversion of NK cells into lymphokine-activated killer cells (LAK) [7].
IFN-γ activates macrophages to produce TNF-α and IL-12, which in turn stimulate NK. IL-1 synthesized by macrophages activates T cells and promotes further production of cytokines. The release of Th1 cytokines, TNF-α and IL-2 converts NK cells into LAK cells. High levels of IL-1, IFN-γ and TNF-α activate blood clotting, which is supplied to the developing embryo.
Thus, the persistence of opportunistic microorganisms and viruses in the endometrium leads to the activation of immunopathological processes, increased synthesis of proinflammatory cytokines (IL-1β, IFN-γ and TNF-α and IL-6), which serves as an obstacle to the creation of local immunosuppression in the preimplantation period , which is necessary to form a protective barrier and prevent miscarriage. In this regard, recovery and rehabilitation of patients with fetal loss syndrome may be associated not only with the elimination of the pathogen, but also with the restoration of defects in immune reactivity when using various immunotherapeutic drugs.
Local cytokine therapy in complex therapy of chronic salpingoophoritis
The problem of chronic inflammatory diseases of the uterine appendages is given great importance due to the increase in their share in the structure of gynecological pathology and the high frequency of complications. Recently, sluggish chronic salpingo-oophoritis (CSO) with frequent relapses, difficult to treat, has prevailed.
A characteristic feature of CSS is the predominance of mixed polymicrobial aerobic-anaerobic processes with transmissible pathogens of the second generation (chlamydia, mycoplasma, genital herpes, etc.).
Work to study the effectiveness of including superlymph in the complex therapy of CSR of various etiologies was carried out on the basis of the Department of Obstetrics and Gynecology of the Russian State Medical University Ph.D. I.N. Rastegaeva under the guidance of Doctor of Medical Sciences, Prof. N.V. Strizhova and Doctor of Medical Sciences HE. Shcheglovitova.
When studying the indicators of cellular and humoral immunity in patients with CSO, the following deviations were noted: moderate lymphocytosis with an increase in the level of T-helper cells and a decrease in cytotoxic T-lymphocytes, an increase in the bactericidal activity of neutrophils and their adhesive properties and at the same time a decrease in phagocytic function. An imbalance in the production of interferon (IFN) in the body was revealed due to a decrease in the ability of leukocytes to produce IFN-γ and IFN-α. Treatment with antibiotics leads to an increase in this deficiency. When studying the local immune processes of the mucous membrane of the reproductive tract in patients with CSR of predominantly viral etiology, a decrease in secretory IgA was revealed due to an almost 2.5-fold increase in the content of IgG and IgM. Long-term persistence of urogenital infection, causing inflammation, disrupts the barrier function of the vagina and cervical canal, promoting the transudation of immunoglobulins from the blood serum, inhibiting the local synthesis of secretory IgA.
Bacteriological examination of cultures of urethral discharge, cervical canal and vaginal contents revealed the growth of opportunistic microbes (staphylococci, enterococci, streptococci) in 85.3% of cases. Most patients had an unfavorable premorbid background, namely: a high incidence of infectious and chronic extragenital diseases.
Superlymph was used in the form of suppositories of 25 units (25 mcg) vaginally at night, one suppository for 7-10 days.
The use of cytokines in complex therapy of herpesvirus and cytomegalovirus infections
The antiviral effect of local cytokine therapy is due to both the direct inhibitory effect of the drug on the replication of the herpes virus, and indirect through the activation of cytotoxic effector cells. Due to stimulation of macrophage-monocyte lineage cells, the mechanisms of both cellular and humoral immune responses are activated.
Currently, herpesvirus infections play a significant role in the occurrence of various diseases in women of reproductive age, including obstetric complications, as well as perinatal pathology. A characteristic feature of lesions due to herpesvirus infection is a high contact infectious index and a chronic course with a tendency to progression and the formation of an immunosuppressive state. In addition, erased, sluggish forms of the disease are increasingly being diagnosed, contributing to the further uncontrolled spread of herpesvirus infection.
In the complex therapy of patients with genital herpes, there has been a tendency to include immunomodulatory drugs, the use of which is pathogenetically justified. Topical cytokine therapy has a direct antiviral effect. It has been shown that this type of drug, depending on the dose, delays or almost completely inhibits the reproduction of HSV-1 in a primary culture of human endothelial cells, and also has an immunomodulatory effect, mediated through the activation of phagocytic cells [3, 4].
When studying the local spectrum of cytokines in the mucus of the cervical canal, the immunomodulatory effect of superlymph on the content of the cytokine IL-8, which stimulates the functional activity of leukocytes at the site of inflammation, was recorded, which can also be significant for the therapeutic effect of the drug.
Assessing the effectiveness of the complex treatment, it should be noted that the timing of relief of relapse of atypical genital herpes was observed in 87.5% of patients after 5 sessions of local intercervical therapy for superlymphomas. At the same time, the HSV antigen ceased to be identified in the cervical canal of the cervix. It is important to emphasize that in 62.5% of patients in this group, by the 3-5th treatment session for superlymphomas, the feeling of local discomfort disappeared, small cracks in the genital mucosa were relieved by the 4-5th treatment session.
In patients with combined HSV and CMV infection, a virological study did not reveal the presence of CMV antigen in the cervical canal even after 5 sessions of intracervical treatment.
Particularly important in terms of the therapy performed was the criterion characterizing the timing of remission. Thus, a significant improvement against the background of the general positive condition of patients with an extension of remission periods to 6-12 months was observed in 75% of patients with an atypical form of herpesvirus infection. Stable remission for 8 months was determined in 74% of patients of group 2 with concomitant CMV infection, while in 11.1% of women the desired pregnancy occurred.
Analyzing the data obtained, we can conclude: the therapeutic effect associated with the use of superlymph in local intracervical therapy in the complex of basic treatment is the rapid elimination of the phenomena of viral endocervicitis, the restoration of resistance mechanisms that inhibit the proliferation of herpes viruses at the site of infection. The use of topical cytokine therapy for superlymphomas has made it possible to increase the effectiveness of basic treatment and achieve stable remission [3].
The use of cytokine therapy in the postoperative period
Particular attention should be paid to the treatment and prevention of purulent-septic complications after cesarean section, endoscopic surgical treatment of tubo-peritoneal infertility, after suturing the perineum. The effectiveness of the treatment depends not only on the surgical technique and the suture material used, but also on the possibility of recurrence and exacerbation of hidden, chronic processes. The cause of repeated recurrence of infections is a violation of the local anti-infective resistance of the mucous membranes against the background of the development of secondary immunodeficiency.
Superlymph is a natural complex of biologically active antimicrobial peptides and cytokines that regulate innate (natural) and acquired (adaptive) immunity. The drug has a direct antimicrobial, direct antiviral, and immunomodulatory effect.
A single (during endoscopic operation) irrigation of the pelvic organs with a superlymph solution and intramuscular administration of imunofan for 5 days is advisable to use in combination with traditional therapy for the treatment and prevention of postoperative complications in patients with chronic inflammatory diseases of the pelvic organs under conditions of laparoscopy.
Thus, the complex composition of superlymph not only makes it possible to expand the scope of its application, but also brings its action as close as possible to the physiological one, since in the body the regulating effect of cytokines on target cells is determined not by the individual molecule, but by their composition. Local cytokine therapy not only replenishes the deficiency of cytokines in various diseases, but also stimulates the synthesis of the body’s own cytokines, is harmless to the body, and its effect is as close as possible to physiological. The drug used for local cytokine therapy, superlymph, is a natural complex of biologically active antimicrobial peptides and cytokines that regulate innate (natural) and acquired (adaptive) immunity. In the body, the regulatory effect of cytokines on target cells is determined not by an individual peptide, but by a composition of cytokines. The future of cytokine therapy lies in the combined use of cytokines in physiological doses.
